Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT01779518 Approved for marketing - Clinical trials for Post-transplant Hepatitis C

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.

NCT ID: NCT01198860 Approved for marketing - CHRONIC HEPATITIS B Clinical Trials

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B

HBV
Start date: n/a
Phase:
Study type: Expanded Access

Phyllanthus Urinaria - Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid combination plus Tenofovir in treatment of acute and chronic hepatitis B. Method the combination of drugs derived from natural and artificial medicaments. Has stronger effect on immune system, effective good against HBV replication. This is a substantial new insight into the pathogenesis of disease, with a clear path toward clinical application, or which would lead to a substantial advance and perfect in management or public health policy.

NCT ID: NCT00042393 Approved for marketing - Chronic Hepatitis B Clinical Trials

An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

Start date: n/a
Phase: Phase 3
Study type: Expanded Access

The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.